Europe

Novartis’ Gilenya earns positive results in extended phase III head-to-head study

Monday, June 11, 2012 02:52 PM

New long-term data for Gilenya (fingolimod), the only oral therapy approved to treat people with relapsing forms of multiple sclerosis (MS), show a sustained efficacy benefit and a consistent safety profile with up to 4.5 years of continuous treatment, according to Switzerland-based Novartis Pharma.

More... »

EMA boosts transparency with online publication of suspected side effects

Friday, June 1, 2012 11:28 AM

The European Medicines Agency has begun publishing suspected side effect reports for medicines authorized in the European Economic Area (EEA) on a new public website: www.adrreports.eu.

More... »

CMO revenue could double in Europe, says Frost & Sullivan

Thursday, May 31, 2012 03:10 PM

New analysis from Frost & Sullivan, "European Pharmaceutical and Biotech Contract Manufacturing Markets," finds that the European pharmaceutical contract manufacturing market earned revenues of $10.02 billion in 2011 and estimates this to reach $20.75 billion in 2018. Over the same period, the European biotech contract manufacturing market is set to expand from $1.21 billion to an estimated $2.67 billion.

More... »

‘Life Science Panorama 2011’ report looks at France

Wednesday, May 23, 2012 11:13 AM

France Biotech, the French association of life science companies, in partnership with Ernst & Young, published the 10th annual “Life Science Panorama,” describing the industry's main trends for 2010-2011 in France and worldwide.

More... »

SGS acquires Vitrology

Wednesday, May 23, 2012 10:29 AM

SGS, a Swiss inspection, verification, testing and certification company, has decided to acquire Vitrology, a biopharmaceutical contract testing organization based in Glasgow, U.K.

More... »

Survey raises questions over NHS research

Tuesday, May 22, 2012 11:36 AM

A survey conducted by OnePoll on behalf of the National Institute for Health Research (NIHR) Clinical Research Network raises concerns that patients could be missing out on opportunities to take part in potentially beneficial clinical trials.

More... »

Wellcome Trust awards Phagenesis $1.5 million for dysphagia treatment

Tuesday, May 22, 2012 10:02 AM

Phagenesis, a U.K. company focused on dysphagia (the inability to swallow), has been awarded $1.5 million from the Wellcome Trust to extend the scope of its dysphagia treatment device, from hospitals into the community.

More... »

GE Healthcare and Karolinska University to advance cell therapy

Tuesday, May 22, 2012 09:38 AM

Karolinska University Hospital Sweden, one of Europe's largest teaching hospitals, and GE Healthcare Life Sciences have formed a research collaboration to drive advances in technologies and workflows for use in the rapidly emerging field of cell therapy.

More... »

PRA expands operations in the Netherlands and U.K.

Monday, May 21, 2012 03:48 PM

PRA, a global CRO, is expanding its operations in the Netherlands and the U.K. to accommodate staff growth and strong client demand for its phase IIa-IIIb service offerings.

More... »

Provence and Neuroptis collaborate on dry eye syndrome

Monday, May 21, 2012 01:03 PM

French companies Provence Technologies, a service provider of specialist fine chemistry, and Neuroptis Biotech, specializing in the discovery and development of innovative therapies in neurology and ophthalmology, are strengthening of their collaboration for transferring the chemical development of Neuroptis Biotech’s drug candidate ML7 and producing the first GMP batches before the end of 2012.

More... »